Skip to main content

Table 2 Baseline clinical characteristics.

From: Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA

Variable Number of subjects (sample size = 3173) Weighted percentages
Symptoms   
   Asymptomatic 1001 30.9
   Lower urinary alone 1832 58.4
   Systemic 340 10.7
Comorbid conditions   
   None 1211 37.2
   1 1008 32.5
   2 520 16.3
   3+ 434 13.9
Health status   
   Excellent 534 16.9
   Good 2104 66.2
   Fair or poor 500 15.9
   Unknown 35 1.0
PSA (ng/ml)   
   <4 294 8.8
   ≥ 4 2675 84.5
   Unknown 204 6.7
Digital rectal examination   
   Abnormal 1741 54.8
   Normal 1033 33.2
   Unknown 399 12.0
Gleason score   
   2 – 4 481 13.9
   5 – 7 2029 65.1
   8 – 10 373 11.6
   Unknown 290 9.4
Tumor stage   
   Local 2796 88.7
   Regional 126 3.7
   Advanced 251 7.6
  1. Legend: PSA = prostate-specific antigen